J J Biagi

Summary

Affiliation: Queen's University
Country: Canada

Publications

  1. ncbi request reprint Systemic treatment policies in ovarian cancer: the next 10 years
    J J Biagi
    Kingston Regional Cancer Centre, Kingston, ON, Canada
    Int J Gynecol Cancer 13:231-40. 2003
  2. doi request reprint A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    J J Biagi
    Department of Oncology, Cancer Centre of South Eastern Ontario, Kingston, Ontario, Canada
    Ann Oncol 22:335-40. 2011
  3. doi request reprint Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis
    James J Biagi
    Department of Oncology, Queen s University, Kingston, Ontario, Canada
    JAMA 305:2335-42. 2011
  4. ncbi request reprint Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients
    A Molckovsky
    Department of Oncology and Department of Obstetrics and Gynecology, Queen s University, Kingston, Ontario, Canada
    Int J Gynecol Cancer 18:8-13. 2008
  5. ncbi request reprint A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma
    J J Biagi
    Department of Hematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Leuk Lymphoma 46:197-206. 2005

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Systemic treatment policies in ovarian cancer: the next 10 years
    J J Biagi
    Kingston Regional Cancer Centre, Kingston, ON, Canada
    Int J Gynecol Cancer 13:231-40. 2003
    ..New standards of care and treatment policies in the next decade will be based on high-quality evidence of improved survival from controlled studies. Many such trials are now ongoing or planned...
  2. doi request reprint A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    J J Biagi
    Department of Oncology, Cancer Centre of South Eastern Ontario, Kingston, Ontario, Canada
    Ann Oncol 22:335-40. 2011
    ..Sunitinib is a multitargeted receptor tyrosine kinase inhibitor. We conducted a two-stage phase II study to evaluate the objective response rate of oral sunitinib in recurrent epithelial ovarian cancer...
  3. doi request reprint Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis
    James J Biagi
    Department of Oncology, Queen s University, Kingston, Ontario, Canada
    JAMA 305:2335-42. 2011
    ..Adjuvant chemotherapy (AC) improves survival among patients with resected colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown...
  4. ncbi request reprint Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients
    A Molckovsky
    Department of Oncology and Department of Obstetrics and Gynecology, Queen s University, Kingston, Ontario, Canada
    Int J Gynecol Cancer 18:8-13. 2008
    ..These results suggest that decreasing the frequency of chemotherapy cycles does not decrease survival. Prospective trials would be required to compare quality of life and cost-effectiveness...
  5. ncbi request reprint A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma
    J J Biagi
    Department of Hematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Leuk Lymphoma 46:197-206. 2005
    ..Further clinical studies of DICE in first relapse and in older patients, possibly with the addition of rituximab, are warranted...